Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro. REDWOOD CITY, Calif., May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on May 7, 2024, the Co ...

Nevro Corp. (NVRO) reported a loss per share of 70 cents in the first quarter of 2024 compared with the year-ago quarter’s loss of 98 cents. The metric beat the Zacks Consensus Estimate by 31.37%.Revenues in DetailNevro registered worldwide revenues of $101.9 million in the first quarter, up 5.8% year over year on a reported basis and 5.6% on a constant-currency basis. The year-over-year growth was largely driven by a product mix shift to Nevro’s latest generation SCS platform, HFX iQ, as well as an increas ...

Nevro (NVRO) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 31.37%. A quarter ago, it was expected that this maker of an electrical implant that treats leg and back pain would post a loss of $0.50 per share when it actually produced a loss of $0.15, delivering a surprise of 70%.Over the last ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of incorporation or organization) (I.R. ...

Exhibit 99.1 Nevro Reports First-Quarter 2024 Financial Results Announces Additional Restructuring Steps to Advance Strategy and Accelerate Profitability Raises Adjusted EBITDA Guidance and Reaffirms Revenue Guidance for Full-Year 2024 Promotes Christofer Christoforou to Chief Operating Officer REDWOOD CITY, California – May 7, 2024 – Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Ind ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of incorporation or organization) ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of incorporation or organization) (I.R.S ...

1Q 2023 Earnings Call Presentation A P RI L 2 6 , 2 0 2 3 Forward-Looking Statements 2 Management uses certain non-GAAP financial measures, most specifically Adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the company's operating performance period over period, analyze the underlying business trends, assess performance relative to competitors and establish operational objectives. • Stock-based compensation expense – The company excludes non-cash costs related to the company's ...

Nevro Corp. (NYSE:NVRO) Q1 2023 Earnings Conference Call April 26, 2023 4:30 PM ET Company Participants Julie Dewey - Chief Corporate Communications and Investor Relations Officer Keith Grossman - Executive Chairman Kevin Thornal - President and CEO Rod MacLeod - Chief Financial Officer Conference Call Participants Larry Biegelsen - Wells Fargo Bill Plovanic - Canaccord Allen Gong - J.P. Morgan Adam Maeder - Piper Sandler Mike Sarcone - Jefferies Anthony Petrone - Mizuho Operator Good afternoon. My name is ...